Disease · MONDO_0002898

skin cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. skin cancer. Diseases, record MONDO_0002898. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002898

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: skin cancer; Open Targets
Open Targets ID: MONDO_0002898; Open Targets
Other names: cancer of zone of skin, malignant neoplasm of skin, malignant neoplasm of the skin, malignant neoplasm of zone of skin, malignant skin neoplasm, malignant skin tumor, malignant skin tumour, malignant tumor of skin, malignant tumor of the skin, malignant tumour of skin, malignant tumour of the skin, malignant zone of skin neoplasm, melanoma and non-melanoma skin cancer, skin cancer, Including melanoma, skin neoplasm, malignant, zone of skin cancer; Open Targets
Disease Ontology: DOID:4159; Disease Ontology
NCI Thesaurus: C2920; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 28 drugs, from DailyMed and TTD; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AVOBENZONE	CHEMBL1200522	Small molecule	Approval	DailyMed	51	1	1	Drugs and targets
ZINC OXIDE	CHEMBL3988900	Small molecule	Approval	DailyMed	36	1	1	Drugs and targets
OCTINOXATE	CHEMBL3183184	Small molecule	Approval	DailyMed	49	0	0	Drugs and targets
TITANIUM DIOXIDE	CHEMBL1201136	Small molecule	Approval	DailyMed	30	0	0	Drugs and targets
DIMETHICONE	CHEMBL2108200		Approval	DailyMed	4	0	0	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Approval	TTD	1	0	0	Drugs and targets
SALICYLIC ACID	CHEMBL424	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AMINOLEVULINIC ACID	CHEMBL601	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
HYDROGEN PEROXIDE	CHEMBL71595	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets36

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
FN1	Fibronectin	1	Fibronectin binding agent	Phase 2	https://conductscience.org/library/genes/2335	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets

1 to 10 of 36

See all 36 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00769379	Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Phase 3	2,014	2022-02-23	Breast Ductal Carcinoma In Situ	TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00578214	Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery	Not applicable	75	2012-02-09	Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety	MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT04913220	A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)	Phase 1/2	46	2026-02-04	Malignant Melanoma, Squamous Cell Carcinoma of Skin	CEMIPLIMAB, PEGENZILEUKIN	Its record names the disease	ClinicalTrials.gov
NCT03767348	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)	Phase 2	340		Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma	NIVOLUMAB, VUSOLIMOGENE ODERPAREPVEC	Open Targets' reading of its record	ClinicalTrials.gov
NCT05614102	A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors	Phase 1	284		Advanced Solid Tumors	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00594542	Comparison of the Total Dose and Efficacy of Two Lidocaine Concentrations Needed for Cutaneous Surgery Local Anesthesia	Not applicable	149		Anesthesia	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT05329792	L19IL2/L19TNF in Skin Cancer Patients	Phase 2	70		BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma	L19IL2, ONFEKAFUSP ALFA	Its record names the disease	ClinicalTrials.gov
NCT05315128	Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers	Phase 2	60		Non-melanoma Skin Cancers	METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04929535	Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment	Phase 2	51		Basal Cell Carcinoma, Squamous Cell Carcinoma of Skin Differentiated	HYDROGEN PEROXIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01861496	Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours	Phase 1/2	50		Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer	CISPLATIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Standard WBI vs WBI, Trastuzumab: deaths from any cause	11 of 1,005	10 of 993	1,998	NCT00769379	Trial comparisons
Standard WBI vs WBI, Trastuzumab: serious adverse events	3 of 998	9 of 990	1,988	NCT00769379	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21238825	RESULT	1	PubMed
42173654	DERIVED	1	PubMed
40627813	DERIVED	1	PubMed
38664936	DERIVED	1	PubMed
33739848	DERIVED	1	PubMed
31399043	DERIVED	1	PubMed
23984897	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002898

GET https://conductscience.org/api/diseases/v1/MONDO_0002898/drugs?page=2

API reference For AI assistants